Inspired by the lotus leaf, researchers at the Wyss and @harvardseas.bsky.social developed Nixe, a PFAS-free water-repellent coating solution that doesn't compromise fabric breathability, durability, or flexibility. #SustainableFutures #PFAS #GreenTech

Wyss researchers developed ReConstruct, an approach that creates living tissue implants from a patient's own cells that can be integrated into their body to offer cancer survivors a more natural, safer reconstruction option following a mastectomy. #BreastCancerAwarenessMonth

We are looking for a Senior Manager of Donor Relations to strategically grow and manage a growing portfolio of new prospects and donors. In this role, you will be a key contributor to expanding the donor base and strengthening stewardship practices that align with the Institute’s strategic goals.

Sepsis is a life-threatening condition, & the third leading cause of neonatal mortality worldwide. Current sepsis diagnostics rely on blood draws that can take days to deliver results. So, Wyss researchers are developing Neosense, a faster & more accurate method for diagnosing sepsis using saliva.

The HarborSite platform overcomes key limitations in current gene therapy approaches by combining two genome editing technologies: genomic safe harbors and highly effective recombinases. Combined, these could enable more predictable, safe, and durable future gene therapies.

Our team is developing injectable immune organs (iNodes) that aim to boost immune responses to enable the formation of lymphoid organs and improve ovarian cancer survival rates by at least 50%. This innovative approach may also benefit other cancers and diseases.

In this podcast interview, the Wyss' Peter Nguyen explores how synthetic biology can turn biofilms into useful materials, embed cell-free systems into wearables, & program probiotics as future therapeutics. He discusses the philosophy behind bioengineering, iGEM, & ideas to tackle plastic pollution.

🩸 The @wyssinstitute.bsky.social has received Wellcome Leap funding to develop the first-ever human Organ Chip model for heavy menstrual bleeding. This work led by Dr. Don Ingber could transform our understanding of #ReproductiveHealth and lead to better treatments. See more: https://bit.ly/3KBzcGe

With funding from Wellcome Leap, the Wyss will develop the first human model of HMB enabling researchers to uncover the causal factors & early biomarkers of HMB progression & identify potential non-hormonal therapeutics by combining multi-omics analysis w/ AI-driven computational approaches.

The GeneSkin team is developing breakthrough mRNA therapies that focus on restoring the function of basal skin stem cells by reducing inflammation and mitigating cellular stress, which is critical for skin rejuvenation and hair restoration.

In this paper in @cp-patterns.bsky.social, Core Faculty member George Church, Postdoc Li Li, and their colleagues outline how LLMs are becoming crucial tools at every stage of drug development to dramatically reduce the time and cost associated with bringing new therapeutics to patients.

Check out this collection of short dispatches from the field of climate microbiology from @quantamagazine.bsky.social, which includes a conversation with Core Faculty member Pam Silver on her vision of engineering microbes that can make carbon-based products and replace the fossil fuel economy.

How can we better harness immune cells to treat disease? Cellular "backpacks," developed at the Wyss, are disc-shaped nanoparticles that can stick to immune cells without being engulfed, and keep them activated against diseases, including cancer and autoimmune diseases.

The Ichor project uses multiomics and gene network data to identify genes that can reverse the biological age of distinct human cell types. It has the potential to treat major age-related diseases, including cardiovascular disease, neurodegeneration, and cancer.

If David Walt could give his teenage self one piece of advice, it would be not to listen to his parents' career advice. Learn more about him in this 20-ish Questions video, showcasing his hobbies, interests, and research. @brighamandwomens.bsky.social @harvardmed.bsky.social @hhmi.org #Wyss20ishQs

What does it take to transform an innovative idea at the bench into a commercializable product that can overcome the valley of death and make a positive societal impact? The Wyss' in-house Business Development Team knows the answers. Learn more about the team and how they support the Wyss community.

As we #ReimagineTheWorld without terminal cancer and work towards that vision, we keep patients like Wyss Scientific Instrument Maker John Caramanica, who continues working even after being diagnosed with metastatic skin cancer, at the top of our minds. #WorldCancerResearchDay

Lorenzo Ferri's group at McGill, in collaboration with Don Ingber, developed patient-specific organs-on-chips that accurately predicted how cancer patients responded to different chemotherapy regimens. Their study opens up exciting new possibilities for drug discovery and precision oncology.

Yesterday, Wyss researchers volunteered at the Cambridge Science Carnival, a family-friendly science extravaganza, where they taught curious minds of all ages about Organ Chips.

In this @natrevbioeng.nature.com paper, Core Faculty member @geochurch.bsky.social, Postdoc Li Li, and their colleagues offer an actionable, practical roadmap for integrating AI tools into protein design, including step-by-step guidance and case studies that demonstrate this roadmap in action.

The Wyss received funding from @wellcomeleap.bsky.social's Missed Vital Signs program to use Organ Chips to create the first-ever human model of heavy menstrual bleeding to uncover root causes & early biomarkers, apply AI to find non-hormonal therapies, & cut the average wait time for treatment.

Namita Sarraf loves to find herself at intersections. As a Wyss postdoc, she's pursuing interests in technology and business development. She's working on two DNA nanotechnology projects while also co-leading the Biotech Interest Group. Learn more about Namita and her work in this month’s #HOWyss.

"We're thinking about any way we can get this to patients. That's the whole point of what we're trying to do," explains Paul Stankey, a researcher in Core Faculty member Jennifer Lewis' lab. Learn what it will take to scale up their work and bring their technologies to patients.

Happy #PostdocAppreciationWeek! Our driven, hardworking, creative postdocs power our engine of innovation towards positive impact. We celebrated these individuals with a lunch, complete with messages of gratitude from across the Institute. Thank you!

Because of the success of the composting program at the Wyss, initiated by our Green Team, and a few other tenant companies, our building is instituting compost collection for everyone to enable all of our work neighbors to prevent pollution and live more sustainably. #PollutionPreventionWeek

Dr. Simon D’Oelsnitz, a Postdoctoral Fellow at the @wyssinstitute.bsky.social, is developing genetically encoded #biosensors. He's applying this technology to PFAS, a.k.a. forever chemicals. Learn more about his system PFASense: https://bit.ly/46iCB3Y

Every day, across the neonatal care unit, babies are pricked to collect their blood for sepsis tests that aren't even very accurate. Researchers at the Wyss and Brigham and Women's Hospital created a more accurate sepsis diagnostics platform that tests easily collected saliva.

Congratulations to Wyss startup Breaking on their plastic-eating microbes being named one of @fastcompany.com's World Changing Ideas of 2025.

The FDA has approved an IND application from Wyss startup eGenesis to move forward with a clinical trial evaluating their genetically modified porcine kidneys for xenotransplantation into patients with end-stage kidney disease.

🔬 Dr. Lorenzo Ferri (The Institute) and Dr. Donald Ingber (Harvard) created an organ-on-a-chip that predicts chemotherapy response — a breakthrough in precision oncology! @cusm-muhc.bsky.social @wyssinstitute.bsky.social @healthsciences.mcgill.ca @harvard.edu 👉 rimuhc.ca/-/an-organ-c...

Congratulations to Wyss Lumineer and CSO of Gameto, Christian Kramme, on being named to MIT Technology Review's 2025 "Innovators Under 35" list.

Core Faculty member Jennifer Lewis’ lab is “part workshop, part incubator for the future of medicine.” Learn what the lab is working on and meet one of the members, Paul Stankey, a doctoral researcher designing blood vessels to keep engineered tissues alive.

Researchers at the Wyss have developed a novel metabolic labeling technology that enables the “tagging” of the surface of T cells with immune-enhancing cytokine molecules, which increases their persistence. It could help expand adoptive T cell therapies to the treatment of solid tumors.

Researchers at the Wyss have developed Crisscross Nanoseed Detection, an enzyme-free DNA nanotechnology for rapid, ultrasensitive, and low-cost detection of infectious disease biomarkers with broad accessibility in point-of-care settings.

Wyss startup GC Therapeutics is overcoming barriers in the development and manufacturing of cell therapies to improve patient access across a broad range of disease areas.

"I want them to enjoy their time in the tissue culture rooms. I arrive every day with a smile because I love what I do, and I want them to feel that way too," explains Juan Mauricio Perez who enables scientific translation by training researchers in tissue culture, biosafety, and lab best practices.

What if aging were optional and extinction reversible? In this episode of Ignition Sequence, Wyss Core Faculty member George Church explores the frontiers of gene therapy, de-extinction, and the future of human health.

We're so proud to share the winners and runners-up from this year's Visions of the Wyss Image Contest. Winners were chosen by a panel of visual artists from our community. Check out the photos ⬇️

Researchers at the Wyss Institute have developed two methods for building arbitrarily shaped nanostructures using DNA, with a focus on translating the technology towards nanofabrication and drug delivery applications.

Wyss researchers developed a new type of catalytic material that is inspired by the honeycomb-like nanostructure of butterfly wings. This allows precious metal catalysts to be strategically placed on the porous scaffold so that the catalytic reaction is much more efficient and cost-effective.

A team led by David Mooney at the Wyss Institute developed a novel tunable biomaterial system that allows researchers to investigate and leverage the effects of tissue mechanics on the state of therapeutic T cells in vitro.

Congratulations to Wyss startup Gameto on closing a $44M Series C financing round to fund a Phase 3 clinical trial of their fertility treatment, improving the IVF process.

Just published in ACS Central Science—our latest work using the Centrifuge Force Microscope to quantify immune-cell interactions. The new setup combines high-throughput force spectroscopy with multichannel fluorescence for single-cell studies. pubs.acs.org/doi/10.1021/...

Simon D’Oelsnitz always has the end-user in mind. As a Wyss Postdoc, he is motivated by conversations with environmental protection agencies, the future users of PFASense, a PFAS diagnostic he’s developing. Learn more about Simon and his work in this month’s #HOWyss.

ICYMI 🧪 @kerrytaylorsmith.bsky.social talked with experts from @wyssinstitute.bsky.social & @imperialnhli.bsky.social about how #NAMs are advancing disease research & drug discovery for #WomensHealth, #CardioSky, #Neuroskyence, & more. www.technologynetworks.com/cell-science...

This year's Validation Projects are driven by multi-talented teams able to develop, validate, and de-risk key technologies, as well as analyze market potential and identify first applications for their approaches. They aim to address Grand Challenges facing patients and our planet.

DNA nanoswitch calipers offer a novel method to deeply probe the structures of proteins rapidly and cheaply, revolutionizing post-translational modification (PTM) research. This transformative approach to proteomics marries DNA nanotechnology with single-molecule manipulation techniques.

Researchers used a new stem cell differentiation method to induce meiosis, a critical step in egg & sperm cell development. This work has potential applications in drug development & fertility treatments.

Wyss researchers have created a microfluidic chip device that can non-invasively monitor a patient’s blood for evidence of clotting. It is being used to initially develop a diagnostic for patients with an aggressive lung cancer, but could be applicable to blood clots in a variety of contexts.

40% of cancer patients who have mastectomies choose to have reconstruction surgery, but that comes with its own risks. So, Wyss researchers developed ReConstruct, which uses adipose tissue assembled from a patient’s own cells and integrates it into their body for a safer, more natural solution.